Market Size of Global Mastopexy Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 5.70 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Mastopexy Market Analysis
The Mastopexy market studied is expected to grow with an estimated CAGR of 5.7% over the forecast period (2022-2027).
As the COVID-19 pandemic progressed with new strains, the safety of ablative resurfacing lasers, micro-needling, and dermatological surgery procedures also seemed to be unsafe. Additionally, the slowing economy and reduced discretionary spending discourage customers from undergoing expensive cosmetic treatments, thus imposing practical restrictions. The Plastic Surgery Statistics Report from the year, 2020 states that a total population of 87,051 patients underwent mastopexy surgery in 2020. Therefore the preference for aesthetic surgeries among the global population is expected to drive the growth of the market during the pandemic period.
The rising female geriatric population and growing demands for aesthetic procedures are estimated to drive market growth during the forecast period. Increased healthcare expenditures and the growing demands for outpatient surgeries are boosting market growth. Additionally, the increasing product launches are expected to contribute to the growth of the market. For, Instance, In May 2021, GC Aesthetics Inc. launched its next generation of breast implants, PERLE. PERLE is a highly innovative line of smooth breast implants that features proprietary surface technology, GCA's industry-leading gel technology, and an enhanced version of the safety features that have underpinned GCA's long-term excellent safety record. In February 2021, Galderma received the approval of RESTYLANE DEFYNE by the United States Food and Drug Administration for the augmentation and correction of mild to moderate chin retrusion for adults. However, factors such as the high cost of mastopexy followed by complications of the surgery are estimated to restrain the market growth during the forecast period.
